

having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R<sub>1</sub> is -R'OR''' wherein R' is C<sub>1</sub>-C<sub>5</sub> straight or branched chain alkyl and R''' is hydrogen or C<sub>1</sub>-C<sub>5</sub> alkyl;

G is -OR<sub>2</sub> wherein R<sub>2</sub> is C<sub>1</sub>-C<sub>5</sub> straight or branched chain alkyl; and

R<sub>3</sub> is C<sub>1</sub>-C<sub>12</sub> straight or branched chain alkyl.

31. The compound of claim 30, wherein R<sub>3</sub> is a straight chain or branched -C<sub>5</sub>-C<sub>9</sub> alkyl.

32. The compound of claim 30, wherein R<sub>3</sub> is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

33. The compound of claim 30, wherein R<sub>1</sub> is -CH<sub>2</sub>OH, G is -OCH<sub>3</sub>, and R<sub>3</sub> is 1,1-dimethyl heptyl.

34. The compound of claim 33, wherein the dotted line represents a double bond.

35. A pharmaceutical composition for preventing the symptoms of, treating, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of a compound of claim 30.

36. The pharmaceutical composition of claim 35 further comprising a pharmaceutically acceptable diluent or carrier.

37. The pharmaceutical composition of claim 36, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution or emulsion prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions.


38. The pharmaceutical composition of claim 35, wherein  $R_3$  is a straight chain or branched  $-C_5-C_9$  alkyl.

39. The pharmaceutical composition of claim 35, wherein  $R_3$  is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

40. The pharmaceutical composition of claim 35, wherein  $R_1$  is  $-CH_2OH$ ,  $G$  is  $-OCH_3$ , and  $R_3$  is 1,1-dimethyl heptyl.

41. The pharmaceutical composition of claim 40, wherein the dotted line represents a double bond.

42. A CB2 specific agonist comprising a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

$R_1$  is  $-R'OR''$  wherein  $R'$  is  $C_1-C_5$  straight or branched chain alkyl and  $R''$  is hydrogen or  $C_1-C_5$  alkyl;

$G$  is  $-OR_2$  wherein  $R_2$  is  $C_1-C_5$  straight or branched chain alkyl; and

$R_3$  is  $C_1-C_{12}$  straight or branched chain alkyl.

43. The agonist of claim 42, wherein  $R_3$  is a straight chain or branched  $-C_5-C_9$  alkyl.

44. The agonist of claim 42, wherein  $R_3$  is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

45. The agonist of claim 42, wherein  $R_1$  is  $-\text{CH}_2\text{OH}$ ,  $G$  is  $-\text{OCH}_3$ , and  $R_3$  is 1,1-dimethyl heptyl.

46. The agonist of claim 45, wherein the dotted line represents a double bond.

CG 47. A pharmaceutical composition for preventing the symptoms of, treating, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of the CB2 specific agonist of claim 40.

48. The pharmaceutical composition of claim 47, further comprising a pharmaceutically acceptable diluent or carrier.

49. The pharmaceutical composition of claim 48, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution or emulsion prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions.

---